ImmuPharma (STU:25I) ROE % Adjusted to Book Value : -19.41% (As of Jun. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ImmuPharma ROE % Adjusted to Book Value?

ImmuPharma's ROE % for the quarter that ended in Jun. 2023 was -80.16%. ImmuPharma's PB Ratio for the quarter that ended in Jun. 2023 was 4.13. ImmuPharma's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -19.41%.

ImmuPharma ROE % Adjusted to Book Value Historical Data

The historical data trend for ImmuPharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma ROE % Adjusted to Book Value Chart

ImmuPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-64.97

-18.17

-29.63

-31.03

-87.22

ImmuPharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-23.86	-47.76	-13.84	-151.43	-19.41

Competitive Comparison of ImmuPharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, ImmuPharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuPharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuPharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ImmuPharma's ROE % Adjusted to Book Value falls into.

ImmuPharma ROE % Adjusted to Book Value Calculation

ImmuPharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-108.15%	/	1.24
	=	-87.22%

ImmuPharma's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-80.16%	/	4.13
	=	-19.41%

ImmuPharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of ImmuPharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuPharma (STU:25I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (STU:25I) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IMM.GB:UK IMM:UK

Address

One Bartholomew Close, London, GBR, EC1A 7BL

Website

https://www.immupharma.co.uk

ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (STU:25I) Headlines

No Headlines